Inactive Instrument

Press Releases Indivior PLC Other OTC

Equities

INVVY

US45579E1055

Press Releases

Unlock all the news: Be the first to know and act before the market!

Indivior Announces the Publication of New Data on the Comparative Effectiveness of Intranasal Nalmefene and IN Naloxone in a Translational Model Assessing the Impact of a Synthetic Opioid Overdose on Respiratory Depression and Cardiac Arrest	06-19	AQ
Indivior : Financial Document	06-05	PU
Indivior : Special Resolution Passed at the 2024 General Meeting Held on May 23, 2024	05-23	PU
Indivior to Host Analyst Teach-in Event in New York City; Reconfirms Full Year 2024 Guidance	05-23	PR
Indivior : Notice of 2024 General Meeting	05-03	PU
Indivior : Draft rules of the Indivior 2024 UK Savings Related Share Option Plan to be considered at the 2024 AGM	03-28	PU
Indivior : Draft rules of the Indivior 2024 Long-Term Incentive Plan to be considered at the 2024 AGM	03-28	PU
Indivior : Annual Report and Accounts for year ended 31 December, 2023.	03-13	PU
Indivior PLC - Court Provides Final Approval of Settlement with Direct Purchaser Class in the Multidistrict Antitrust Litigation, Final Court Approval Concludes the Antitrust Multidistrict Litigation	03-01	AQ
Indivior to pay £385m to settle Suboxone lawsuits	24/10/23	AQ
Indivior : Reaches Agreement with Direct Purchasers to Resolve Antitrust Multi-District Litigation; Provides Preliminary Q3 and YTD 2023 Results	23/10/23	PU
Strategic Divestment of C4XD's Orexin-1 Receptor Antagonist Programme to Indivior for GBP15.95 Million	02/08/23	AQ
Indivior Announces H1 and Q2 2023 Financial Results	28/07/23	AQ
Indivior : Financial Document	15/06/23	PU
Indivior to Commence Trading on Nasdaq; Company to Ring Opening Bell June 14 to Bring Awareness to Addiction Treatment; Company Will Maintain Premium Listing on London Stock Exchange	12/06/23	AQ
Indivior : Financial Document	06/06/23	PU
Indivior Reaches Agreement with States' Attorneys General and District of Columbia to Resolve Antitrust Multi-District Litigation Claims	05/06/23	AQ
Maker of anti-addiction drug Suboxone reaches $102.5 million settlement over antitrust claims	02/06/23	AQ
Indivior PLC Form 20-F Registration Statement for Additional US Listing	24/05/23	AQ
Indivior Announces U.S. Food and Drug Administration Approval of OPVEEÂ® (nalmefene) Nasal Spray, An Opioid Overdose Rescue Medicine for Natural and Synthetic Opioids Like Fentanyl	23/05/23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Indivior PLC Other OTC

Equities

INVVY

US45579E1055

Press Releases

Filters